O Sobczyk1, A P Crawley2, J Poublanc2, K Sam3, D M Mandell2, D J Mikulis4, J Duffin5, J A Fisher6. 1. From the Institute of Medical Science (O.S., D.J.M., J.A.F.) o.pucci@mail.utoronto.ca. 2. Joint Department of Medical Imaging and the Functional Neuroimaging Laboratory (A.P.C., J.P., K.S., D.M.M., D.J.M.). 3. Department of Physiology (K.S., J.D., J.A.F.), University of Toronto, Toronto, Canada Joint Department of Medical Imaging and the Functional Neuroimaging Laboratory (A.P.C., J.P., K.S., D.M.M., D.J.M.). 4. From the Institute of Medical Science (O.S., D.J.M., J.A.F.) Joint Department of Medical Imaging and the Functional Neuroimaging Laboratory (A.P.C., J.P., K.S., D.M.M., D.J.M.). 5. Department of Physiology (K.S., J.D., J.A.F.), University of Toronto, Toronto, Canada Department of Anaesthesia and Pain Management (J.D., J.A.F.), University Health Network, Toronto, Canada. 6. From the Institute of Medical Science (O.S., D.J.M., J.A.F.) Department of Physiology (K.S., J.D., J.A.F.), University of Toronto, Toronto, Canada Department of Anaesthesia and Pain Management (J.D., J.A.F.), University Health Network, Toronto, Canada.
Abstract
BACKGROUND AND PURPOSE: Changes in cerebrovascular reactivity can be used to assess disease progression and response to therapy but require discrimination of pathology from normal test-to-test variability. Such variability is due to variations in methodology, technology, and physiology with time. With uniform test conditions, our aim was to determine the test-to-test variability of cerebrovascular reactivity in healthy subjects and in patients with known cerebrovascular disease. MATERIALS AND METHODS: Cerebrovascular reactivity was the ratio of the blood oxygen level-dependent MR imaging response divided by the change in carbon dioxide stimulus. Two standardized cerebrovascular reactivity tests were conducted at 3T in 15 healthy men (36.7 ± 16.1 years of age) within a 4-month period and were coregistered into standard space to yield voxelwise mean cerebrovascular reactivity interval difference measures, composing a reference interval difference atlas. Cerebrovascular reactivity interval difference maps were prepared for 11 male patients. For each patient, the test-retest difference of each voxel was scored statistically as z-values of the corresponding voxel mean difference in the reference atlas and then color-coded and superimposed on the anatomic images to create cerebrovascular reactivity interval difference z-maps. RESULTS: There were no significant test-to-test differences in cerebrovascular reactivity in either gray or white matter (mean gray matter, P = .431; mean white matter, P = .857; paired t test) in the healthy cohort. The patient cerebrovascular reactivity interval difference z-maps indicated regions where cerebrovascular reactivity increased or decreased and the probability that the changes were significant. CONCLUSIONS: Accounting for normal test-to-test differences in cerebrovascular reactivity enables the assessment of significant changes in disease status (stability, progression, or regression) in patients with time.
BACKGROUND AND PURPOSE: Changes in cerebrovascular reactivity can be used to assess disease progression and response to therapy but require discrimination of pathology from normal test-to-test variability. Such variability is due to variations in methodology, technology, and physiology with time. With uniform test conditions, our aim was to determine the test-to-test variability of cerebrovascular reactivity in healthy subjects and in patients with known cerebrovascular disease. MATERIALS AND METHODS: Cerebrovascular reactivity was the ratio of the blood oxygen level-dependent MR imaging response divided by the change in carbon dioxide stimulus. Two standardized cerebrovascular reactivity tests were conducted at 3T in 15 healthy men (36.7 ± 16.1 years of age) within a 4-month period and were coregistered into standard space to yield voxelwise mean cerebrovascular reactivity interval difference measures, composing a reference interval difference atlas. Cerebrovascular reactivity interval difference maps were prepared for 11 male patients. For each patient, the test-retest difference of each voxel was scored statistically as z-values of the corresponding voxel mean difference in the reference atlas and then color-coded and superimposed on the anatomic images to create cerebrovascular reactivity interval difference z-maps. RESULTS: There were no significant test-to-test differences in cerebrovascular reactivity in either gray or white matter (mean gray matter, P = .431; mean white matter, P = .857; paired t test) in the healthy cohort. The patient cerebrovascular reactivity interval difference z-maps indicated regions where cerebrovascular reactivity increased or decreased and the probability that the changes were significant. CONCLUSIONS: Accounting for normal test-to-test differences in cerebrovascular reactivity enables the assessment of significant changes in disease status (stability, progression, or regression) in patients with time.
Authors: Olivia Sobczyk; Anne Battisti-Charbonney; Julien Poublanc; Adrian P Crawley; Kevin Sam; Jorn Fierstra; Daniel M Mandell; David J Mikulis; James Duffin; Joseph A Fisher Journal: J Cereb Blood Flow Metab Date: 2014-11-12 Impact factor: 6.200
Authors: Julien Poublanc; Adrian P Crawley; Olivia Sobczyk; Gaspard Montandon; Kevin Sam; Daniel M Mandell; Paul Dufort; Lashmikumar Venkatraghavan; James Duffin; David J Mikulis; Joseph A Fisher Journal: J Cereb Blood Flow Metab Date: 2015-07-01 Impact factor: 6.200
Authors: J Fierstra; O Sobczyk; A Battisti-Charbonney; D M Mandell; J Poublanc; A P Crawley; D J Mikulis; J Duffin; J A Fisher Journal: J Physiol Date: 2013-09-30 Impact factor: 5.182
Authors: Daniela Flück; Andrew E Beaudin; Craig D Steinback; Gopukumar Kumarpillai; Nandavar Shobha; Cheryl R McCreary; Stefano Peca; Eric E Smith; Marc J Poulin Journal: Front Physiol Date: 2014-02-19 Impact factor: 4.566
Authors: L McKetton; L Venkatraghavan; C Rosen; D M Mandell; K Sam; O Sobczyk; J Poublanc; E Gray; A Crawley; J Duffin; J A Fisher; D J Mikulis Journal: AJNR Am J Neuroradiol Date: 2018-12-20 Impact factor: 3.825
Authors: Nicholas G Evanoff; Bryon A Mueller; Kara L Marlatt; Justin R Geijer; Kelvin O Lim; Donald R Dengel Journal: Clin Physiol Funct Imaging Date: 2020-02-16 Impact factor: 2.273
Authors: William Reginold; Kevin Sam; Julien Poublanc; Joe Fisher; Adrian Crawley; David J Mikulis Journal: Hum Brain Mapp Date: 2019-05-21 Impact factor: 5.038
Authors: James Duffin; Olivia Sobczyk; Adrian Crawley; Julien Poublanc; Lashmi Venkatraghavan; Kevin Sam; Alan Mutch; David Mikulis; Joseph Fisher Journal: Hum Brain Mapp Date: 2017-08-07 Impact factor: 5.038
Authors: Moss Y Zhao; Amanda Woodward; Audrey P Fan; Kevin T Chen; Yannan Yu; David Y Chen; Michael E Moseley; Greg Zaharchuk Journal: J Cereb Blood Flow Metab Date: 2021-11-22 Impact factor: 6.960
Authors: Olivia Sobczyk; Jorn Fierstra; Lakshmikumar Venkatraghavan; Julien Poublanc; James Duffin; Joseph A Fisher; David J Mikulis Journal: Front Physiol Date: 2021-07-07 Impact factor: 4.566
Authors: Michael J Ellis; Lawrence N Ryner; Olivia Sobczyk; Jorn Fierstra; David J Mikulis; Joseph A Fisher; James Duffin; W Alan C Mutch Journal: Front Neurol Date: 2016-04-29 Impact factor: 4.003
Authors: W Alan C Mutch; Michael J Ellis; Lawrence N Ryner; Marc P Morissette; Philip J Pries; Brenden Dufault; Marco Essig; David J Mikulis; James Duffin; Joseph A Fisher Journal: Front Neurol Date: 2016-07-08 Impact factor: 4.003